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Abstract Human prostate cancers (PCa) express great variability in their ability to metastasize to bone. The
identification of molecules associated with aggressive phenotypes will help to define PCa subsets and will ultimately lead
to better treatment strategies. The chemokine stromal-derived factor-1 (SDF-1 or CXCL12) and its receptor CXCR4 are
now known to modulate the migration and survival of an increasing array of normal and malignant cell types including
breast, pancreatic cancers, glioblastomas, and others. The present investigation extends our previous investigations by
determining the expression of CXCR4 and CXCL12 in humans using high-density tissue microarrays constructed from
clinical samples obtained from a cohort of over 600 patients. These data demonstrate that CXCR4 protein expression is
significantly elevated in localized and metastastic cancers. At the RNA level, human PCa tumors also express CXCR4 and
message, but overall, they were not significantly different suggesting post-transcriptional regulation of the receptor plays a
major role in regulating protein expression. Similar observations were made for CXCL12 message, but in this case more
CXCL12 message was expressed by metastastic lesions as compared to normal tissues. PCa cell lines also express CXCL12
mRNA, and regulate mRNA expression in response to CXCL12 and secrete biologically active protein. Furthermore,
neutralizing antibody to CXCL12 decreased the proliferation of bone homing LNCaP C4-2B and PC3 metastastic tumor
cells. These investigations provide important new information pertaining to the molecular basis of how tumors may ‘home’
to bone, and the mechanisms that may account for their growth in selected end organs. J. Cell. Biochem. 89: 462–473,
2003.  2003 Wiley-Liss, Inc.
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Prostate cancer (PCa) is a common neoplasm
and the second leading cause of cancer deaths
in American males [Pienta and Esper, 1993;
Parker et al., 1996; Weingartner et al., 1998].
Despite numerous advances, the high mortality
rate is principally due to the spread of malignant
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cells to many tissues including bone [Jacobs,
1983; Koutsilieris, 1993]. As a result, there is
a growing interest in the early detection and
screening of men for PCa, and for a greater
understanding of the mechanisms that lead to
metastasis (Met) particularly to bone.
Met isacomplicated,multi-stepprocess [Fidler,
1999]. Malignant cells must initially ‘‘escape’’
from the primary tumor, invade into the sur-
rounding tissues and enter into the vascular
circulation. If they are able to survive in the
blood stream, they must arrest at a secondary
target site, cross the vascular barrier, and mi-
grate into the extra vascular connective tissues.
Subsequently, the tumor cells must proliferate
thereby establishing a secondary (metastatic)
colony. These events involve numerous cell–cell
and cell–matrix adhesive interactions, which
are mediated by cell surface adhesion mole-
cules. Numerous hypotheses have been put
forth to explain the predilection of PCa for bone.
These include the anatomic configuration of
venous drainage system from the prostate to
the spine, the presence of ‘‘leaky’’ sinusoids in
the bone marrow, the elaboration of ‘‘tumor-
attracting’’ chemotactic factors by bone and/
or other marrow cells, and the production of
growth factors in the marrow that stimulate
proliferation and survival of seeded cells [Geldof,
1997a]. All of these possibilities are likely to
be important determinants of prostate Met to
bone [Geldof, 1997b]. Yet despite our increasing
understanding in each of these areas the molec-
ular basis for how these tumors preferentially
‘home’ to bone remains to be determined.
The Met of circulating prostate carcinoma
cells is functionally akin to the homing behavior
of hematopoietic cells to the bone marrow where
many molecules are known to regulate hemato-
poietic stem cell homing, participating as both
chemoattractants and regulators of cell matura-
tion. Considerable attention has been focused
on a large family of chemotactic proteins called
chemokines [Baggiolini, 1998]. Chemokines are
classified based upon the relative position of
cysteine residues near the amino-terminus into
four major families: CC, CXC, C, CX3C. Since
the first chemokine receptor (IL-8R) was cloned,
more than 20 receptors have been identified.
All are members of the large family of seven-
transmembrane G protein-coupled receptors
with considerable overlap in ligand–receptor
specificity, thereby adding considerable com-
plexity to the system.
Chemokines play significant roles in normal
development, inflammation, infection, athero-
sclerotic progression, and angiogenesis [Rottman,
1999; Rossi and Zlotnik, 2000; Gerard and
Rollins, 2001]. In addition, they are known to
participate in hematopoietic stem cell homing.
Here a CXC chemokine stromal-derived factor-
1 (SDF-1 or CXCL12) and its receptor, CXCR4
appear to be critical determinants in these
events [Aiuti et al., 1999b; Kim and Broxmeyer,
1999]. This was demonstrated most convin-
cingly in gene knockout investigations showing
that normal fetal liver hematopoiesis occurs in
homozygous animals, but marrow engraftment
by hematopoietic cells does not [Nagasawa et al.,
1996; Aiuti et al., 1999a; Peled et al., 1999].
In addition, CXCR4 expression levels correlate
with the ability of human progenitors to engraft
into the marrow in nude mice, and antibody to
CXCR4 prevented the engraftment of progeni-
tors in the bone marrow [Peled et al., 1999].
Finally, osteoblasts and marrow endothelial
cells express CXCL12, which may thereby loca-
lize hematopoietic progenitor cells in the marrow
[Hamada et al., 1998; Wang et al., 1998; Peled
et al., 1999].
Recently, we hypothesized that metastatic
prostate carcinomas also utilize the CXCL12/
CXCR4 pathway to localize to the bone marrow
[Taichman et al., 2002]. We previously demon-
strated that PCa cell lines express CXCR4 and
that they adhere to endothelium and migrate in
response to CXCL12 [Taichman et al., 2002].
The present investigation further explored this
hypothesis by determining whether CXCR4 and
CXCL12 are expressed by human PCa in vivo
and if receptor expression alters PCa cell acti-
vities that are consistent with metastatic
behavior. These investigations provide impor-
tant new information pertaining to the molecu-
lar basis of how tumors ‘home’ to bone, and will
facilitate the development of new strategies
for preventing or minimizing prostate Met.
MATERIALS AND METHODS
Tissue Microarray
High-density tissue microarrays were con-
structed from clinical samples obtained from a
cohort of over 600 patients, who underwent
radical retro pubic prostatectomy at the Univer-
sity of Michigan as a primary therapy (i.e., no
preceding hormonal or radiation therapy) for
PCa from 1994 to 1998. These were provided
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from the University of Michigan Comprehen-
sive Cancer Center Histology and Immuno-
peroxidase Core courtesy of Dr. Mark Rubin
(Department of Urology and Internal Medicine,
University of Michigan, Ann Arbor, MI) as
detail previously [Rubin et al., 2000]. Tumors
were graded using the Gleason grading system
and examined to identify areas of benign pro-
state, PCa, and bone Met. The formalin-fixed,
paraffin-embedded tissues were dewaxed and
placed in a pressure cooker containing 0.01 M
buffered sodium citrate solution (pH 6.0), boiled
and chilled to room temperature for antigen
retrieval. The slides were then incubated over-
night at room temperature with anti-human
CXCR4 antibody diluted 1:100 (10 mg/ml),
MBA171 (IgG2a) (Clone 44708.111, R&D Sys-
tems, Minneapolis, MN). A streptavidin/biotin
detection method with 3,30-diaminobenzidine
tetrahydrochloride (DAB) was employed for
signal detection and Harris hematoxylin was
used as a counter-stain. Immunostaining inten-
sity was scored by a genito-urinary pathologist
(MAR) as absent (1), weak (2), moderate (3), or
strong (4). Scoring was performed blind using
a telepathology system without knowledge of
overall Gleason score (e.g., tumor grade), tumor
size, or clinical outcome [Perrone et al., 2000].
Secondary Data Analysis for CXCL12 and
CXCR4 Expression in Human PCa
Secondary data analysis was performed on
data published by Dhanasekaran et al. [2001].
Using a 10,000 human cDNA micoarray which
included5,520 known, named genes and 4,464
ESTs, the authors determined the gene-expres-
sion profiles of RNA obtained from more than
50 normal and neoplastic prostate specimens
[Dhanasekaran et al., 2001].Primary data anal-
ysis was performed with a Genepix software
package on Cy3-to-Cy5 ratios determined for
the individual genes along with various other
quality-control parameters (e.g., intensity over
local background) [Dhanasekaran et al., 2001].
Supplementary information from Dhanasekaran
et al. [2001] were imported into a Microsoft Excel
database and data clustered into normal associ-
ated tissues (NAP), benign hyperplasia (BPH),
localized cancer (PCa), and Met. The normaliz-
ed mean and standard deviation (SD) values for
CXCR4 and CXCL12 were evaluated for sig-
nificance with Instat 4.0 (GraphPAD software)
using one-way analysis of variance (ANOVA),
with the level of significance set at P< 0.05.
PCa Cell Lines
PC-3 cells originally isolated from a vertebral
Met of a human PCa patient, were obtained
from American Type Culture Collection (Rock-
ville, MD) and maintained in RPMI 1640 con-
taining 10% fetal bovine serum (FBS), 100 U/ml
penicillin, and 100 mg/ml streptomycin (here-
after called growth medium). LNCaP cells were
isolated from a lymph node of a patient with
disseminated bony and lymph node involve-
ment. The LNCaP cells and LNCaP sub lines
(C4 and C4-2B cells) were originally obtained
from UroCor, Inc. (Oklahoma City, OK). The
VCaP cell line was originally harvested at
autopsy from a metastatic lesion to a lumbar
vertebral body of a patient with hormone re-
fractory PCa and aseptically xenografted into
SCID mice [Korenchuk et al., 2001]. PCa cell
lines were passaged and allowed to grow to
confluence over 5 days. The cells were cultured
in RPMI Medium 1640 supplemented with
10% FBS, 1% penicillin–streptomycin, and 1%
L-glutamine. For the production of PCa cell
conditioned medium, the cells were replated at
2 104 cells/cm2 into 24-well tissue culture
plates and incubated in growth medium. After
confluence the cells were washed with phos-
phate-buffered saline (PBS) and medium re-
placed with growth medium and then incubated
for an additional 72 h. Thereafter, the condi-
tioned media were collected and frozen after
passage through a 0.22 mM filter. Non-condi-
tioned media were similarly treated and used as
a negative control.
Mixed Human Bone Marrow Stromal
Cell (BMSC) Conditioned Medium
and Human Osteoblasts (HOB)
Human bone marrow cells were obtained
from healthy adult volunteers by iliac crest
puncture and aspiration into preservative-free
heparin under a protocol approved by the Uni-
versity of Michigan’s Investigational Review
Board. Mononuclear cells were isolated by
density separation on Ficoll-Hypaque (specific
gravity 1.077). Following plastic adherence at
378C for 2 h, the non-adherent cells were re-
moved and the cultures were allowed to reach
confluence (1–2 weeks). The cells were used
after 2nd passage in Iscove’s Modified Dulbecco’s
Medium (IMDM medium; Life Technologies,
Grand Island, NY) with 10% FBS (Life Tech-
nologies), 10% equine serum (Life Technologies)
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and 1 mM hydrocortisone (Life Technologies).
Conditioned medium was collected from when
2nd passage cells had reached 85% confluent.
The cells were washed, replaced with serum
reduced AIM V medium, incubated for an ad-
ditional 24 h, then conditioned, and media not
exposed to cells were collected and frozen after
passage through a 0.22 mM filter.
Enriched human osteoblast cultures were
established using modifications of methods
described by Robey and Termine [1985]. Normal
human trabecular bone obtained from patients
undergoing orthopedic surgery in accordance
with the University of Michigan’s Investiga-
tional Review Board, was cleaned of loosely
adherent tissue, ground to produce a uniform
particle size (size1 mm2) (BioComp Minimill,
W. Lorenz, Jacksonville, FL) and incubated in
1 mg/ml bacterial collagenase (Type B, Boeh-
ringer Mannheim Biologicals, Indianapolis, IN)
in DMEM. The explants cultured until conflu-
ent in a 1:1 (vol/vol) mixture of Ham’s F12/
DMEM (Biofluids, Rockville, MD) with low
Caþ2 and 10% heat inactivated FBS. There-
after, the cultures were maintained in calcium
replete Ham’s F12/DMEM (1:1 vol/vol) medium
containing 10% heat inactivated serum, anti-
biotics, 10 mM b-glycerol phosphate, and 10 mg/
ml L-ascorbate. Characterization and culture
of the resulting cells has been described in de-
tail previously [Taichman and Emerson, 1994;
Taichman and Emerson, 1998].
CXCL12 ELISA
Conditioned medium was collected over time
and stored at 808C until assayed by antibody
sandwich ELISA assembled with components
purchased from R&D Systems (sensitivity 31.25
pg/ml, range 62.5–5,000 pg/ml; R&D Systems).
Proliferation Assays
PCa cells were washed three times in PBS,
and 5 103 cells plated in triplicate in 96-well
flat-bottomed tissue culture plates (BD Bio-
sciences, Palo Alto, CA) in 0.1 ml in growth
medium. Log serial dilutions of recombinant
human CXCL12 was added alone or in combina-
tion with BMSC conditioned medium (0, 10,
25 %) over a dose range of (0.1–200 ng/ml) (R&D
Systems). Thereafter, the cultures were incu-
bated in an atmosphere of 5% CO2 and 5% O2
at 378C for 4 days. Proliferation was quantified
by either colorimetric assay using 3-(4,5-
dimethylazol-2yl)-2,5-diphenyltetrazolium bro-
mide (MTT) or sodium 30-(1-(phenylaminocarbo-
nyl)-tetrazolium)-bis (4-methoxy-6-nitro(XTT)
(Sigma, St. Louis, Missouri) and read on a
multiwell scanning spectrophotometer (Molec-
ular Devices Corp., Sunnyvale, CA). The effect
of PCa-derived CXCL12 proliferation was eval-
uated by the addition of neutralizing anti-
CXCL12 monoclonal antibodies (R&D Systems)
or IgG control, or vehicle were added to a final
concentration of 120 mg/ml daily for 3 days,
where proliferation was determined by manual
hemocytometer counting or quantified by MTT
assay.
Real Time RT-PCR
The PCa cell lines (LNCaP, LNCaP C4-2B,
and PC3) were passaged and cultured in RPMI
Medium 1640, supplemented with 10% FBS, 1%
penicillin–streptomycin, and 1% L-glutamine.
After confluence, the media were removed and
replaced with serum free media, and CXCL12 at
0 or 200 ng/ml, were added for 1–3 h. The cells
were then lysed directly in Trizol1 according
to the directions of the manufacturer (Trizol,
Invitrogen, Carlsbad, CA). RNA integrity and
purity was checked by electrophoresis with
ethidium bromide and absorbance at A260/A280.
First strand cDNA synthesis was performed
on 1 mg of total RNA using random hexamers
and QuantiTect SYBR1-Green PCR Kit
for quantitative, two step real-time RT-PCR
(Qiagen, Valencia, CA). Amplification primers
were designed using PrimerExpressTM soft-
ware (Applied Biosystems, Foster City, CA) to
cross intron/exon boundaries and were vali-
dated by (i) sequencing the resulting product
using the University of Michigan DNA Sequen-
cing Core Facilities, and by (ii) determining
cross-reactivity using BLAST (http://www.ncbi.
nlm.nih.gov/BLAST/), those with the lowest
potential were synthesized. The sequences of
the forward and reverse primers of CXCR4
were 50-TGACGGACAAGTACAGGCTGC and
50-CCAGAAGGGAAGCGTGATGA, respectively.
The sequences of the forward and reverse
primers of CXCL12 were 50-TGCCAGAGC-
CAACGTCAAG, 50-CAGCCGGGCTACAATCT-
GAA. The PCR product was detected as an
increase in fluorescence with the ABI PRISM
7700 instrument (Applied Biosystems). PCR was
performed with 12.5 ml of SYBR PCR master
mixture, each of the primers at a concentration
of 100 nM, and 1 ml of RT product in a total
volume of 25 ml. The 2-step PCR reaction (958C
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for 15 s, 608C for 60 s) was run for 40 cycles after
an initial single cycle of 958C for 15 min to
activate the Taq polymerase. The mRNA levels
were expressed either in absolute copy number
or relative copy numbers (% control) normalized
against 18S mRNA (Ambion QuantumRNATM
18S Universal Primers) and a standard curve
constructed from serial dilutions of a purified
CXCL12 and CXCR4 cDNA fragment cloned
from PCR product obtained by classical PCR.
Statistical Analysis
Differences in CXCR4 protein expression
were evaluated statistically using the mean
scores from each case for each prostate tissue
type (e.g., benign, localized PCa, and hormone-
refractory metastatic PCa). To test for signifi-
cant differences in the mean CXCR4 protein
expression among all tissue types, we performed
a one-way ANOVA test. To determine differ-
ences between all pairs (e.g., localized PCa vs.
benign), we performed a post-hoc analysis using
the Scheffe method [Rubin et al., 2000]. The
mean expression scores for all benign, localized
PCa, and bone Met examined cases are pre-
sented in a graphical format using error bars
with 95% confidence intervals (CI). Culture
data were expressed as meanSD. Statistical
differences between the means for the different
groups were evaluated with Instat 4.0 (Graph-
PAD software) using one-way ANOVA, with
the level of significance at P< 0.05. All in vitro
experiments were repeated two to three times
with triplicate samples and similar results were
obtained.
RESULTS
Our premise is that CXCL12 and its CXCR4
receptor help to define the bone specific Met of
prostate carcinomas. To address the hypothesis,
we previously demonstrated that osteoblasts in
the bone marrow express CXCL12, and that
PCa cell lines express CXCR4 and are function-
ally responsive to the ligand. In the present
investigation, we determined if PCA cells ex-
press the CXCR4 receptor in humans.
To examine the widest range of PCa speci-
mens, high-density tissue microarrays were
constructed from clinical samples obtained from
a cohort of over 600 patients, who underwent
radical retro pubic prostatectomy at the Uni-
versity of Michigan as a primary therapy (i.e.,
no preceding hormonal or radiation therapy) for
clinically localized PCa from 1994 to 1998 with
approval from University of Michigan IRB
(Provided by Dr. Mark Rubin, University of
Michigan from the Rapid Autopsy Program
which have been described in detail previously
[Rubin et al., 2000]). Tumors were graded using
the Gleason grading system and examined to
identify areas of benign prostate, PCa and bone
Met. Staining of four tissue microarrays with
monoclonal antibody revealed moderate-to-
strong CXCR4 protein expression in clinically
localized PCa samples with cytoplasmic and
nuclear localization (Fig. 1A,B,C). Levels of
CXCR4 protein expression in the malignant
epithelia were greater than in the benign
epithelia (Fig. 1D), whereas normal epithelium
predominately demonstrated weak cytoplasmic
with strong nuclear staining (Fig. 1D). Both
prostatic intraepithelial neoplasia and some
atrophic lesions, thought to be potentially pre-
cancerous lesions demonstrated cytoplasmic
staining of CXCR4 but as there were too few
samples they were not included in our anal-
ysis [Putzi and De Marzo, 2000]. High-grade
(Gleason score, 4þ 4¼ 8) (Fig. 1E) and low-
grade PCa (not shown) demonstrated strong
cytoplasmic staining. Similar staining was ob-
served in bone metastases (Fig. 1F).
Quantitative analysis of the expression
CXCR4 receptors in human PCa was performed
by scoring protein expression as negative
(score¼ 1), weak (2), moderate (3), and strong
(4). Differences in CXCR4 protein expression
were evaluated statistically using the mean
score results from each case for each prostate
tissue type. As is shown in Figure 2, immuno-
Fig. 1. The expression of CXCR4 in human prostate cancers
(PCa). Formalin-fixed paraffin-embedded tissues were dewaxed
and placed in a pressure cooker containing 0.01 M buffered
sodium citrate solution (pH 6.0), boiled and chilled to room
temperature for antigen retrieval. The slides were incubated
overnight at room temperature with anti-human CXCR4 antibody
diluted 1:100 (10 mg/ml). MBA171 (IgG2a) (Clone 44708.111,
R&D Systems, Minneapolis, MN). A streptavidin/biotin detection
method with 3,30-diaminobenzidine tetrahydrochloride (DAB)
was employed for signal detection. Harris hematoxylin was used
as a counter-stain CXCR4 is over expressed in PCa. Representa-
tive elements of a tissue microarray stained with anti-CXCR4
antibody showing localized and invasive prostate carcinomas (A,
B, C). Staining is weak in benign prostatic hyperplasia (BPH) (D),
but strong in the cytoplasm of localized PCa (E), and metastastic
bone lesions (F). Original magnification1 (A),10 (B),20 (C),
200 (D, E, F). [Color figure can be viewed in the online issue,
which is available at www.interscience.wiley.com.]
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Fig. 1.
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histochemical data show that the expression
of CXCR4 increased with increasing tumor
aggressiveness. Secondary data analysis of mi-
croarray data collected for the purposes of a
prior investigation was also performed to deter-
mine CXCR4 mRNA levels [Shibuta, 2002].
Using computed t-statistics, we observed that
the CXCR4 RNA levels in benign hyperplastic,
localized and metastatic tumors were elevated
relative to normal adjacent tissues (Fig. 3). In
this case, however, the mean peak in CXCR4
mRNA expression was observed in the benign
hyperplastic disease with CXCR4 mRNA ex-
pression declining with increasing tumor grade,
although statistically there were no significant
differences.
During organogenesis, CXCR4 and CXCL12
are known to have dynamic and complementary
expression patterns [McGrath et al., 1999].
These include the apposed expression of CXCR4
and CXCL12 in mesoderm/ectoderm during
gastrulation, vascular endothelium/mesoderm,
thyroid endodermal epithelium/mesenchyme
mesenchyme [McGrath et al., 1999]. We, there-
fore, examined whether CXCL12 was expressed
by human PCa themselves in a similar fashion.
Unfortunately, we were not able to consistently
demonstrate CXCL12 at the protein level using
our tissue microarrays, although weak nuclear
staining for CXCL12 was frequently observed
in localized PCa cancers (data not presented).
Therefore, CXCL12 expression was examined
at the level of mRNA in human PCa by secon-
dary data analysis of microarray data collected
for the purposes of a prior study [Shibuta, 2002].
The data demonstrate that metastastic PCa cells
express significantly more mRNA for CXCL12
than do normal prostatic tissues (Fig. 3). There
was no significant differences observed between
normal tissues and BPH and localized tumors.
Given that the expression of CXCL12 mRNA
was elevated in metastastic disease, but not
in the localized tumor, we hypothesized that
CXCL12 might serve as a growth factor for
metastatic disease once the tumor had lodged in
a metastastic site. To test this possibility, PCa
cell lines were examined for their expression
and secretion of CXCL12 as well as CXCR4.
Here real-time RT-PCR was employed to deter-
mine the level to which the messages were
expressed in PCa cells. In addition, we evalu-
ated whether CXCL12 and CXCR4 mRNA could
be regulated by CXCL12. For direct compar-
isons between the experimental conditions
and cell types, a CXCL12 and CXCR4 mRNA
standard curve were generated and used to
normalize cycle data to copy number (Fig. 4A).
The data demonstrate that each of the PCa cells
examined expressed mRNA for CXCRL12 as
well as CXCR4 (Fig. 4A). The basal levels of
CXCL12 mRNA were highest in the LNCaP C4-
2B and LNCaP cell lines followed by the PC3
Fig. 2. Quantitative evaluation of the expression of CXCR4 is in
PCa and bone metastases. Immunostaining intensity was scored
as either absent (1), weak (2), moderate (3), or strong (4). The
mean expression scores for all benign, localized PCa, and bone
metastasis (Met) examined cases are presented in a graphical
format using error bars with 95% confidence intervals (CI).
Statistically significant differences were noted between benign
hyperplasia (BPH) and localize cancer (PCa) or metastastic
cancer (Met PCA) for P<0.05 (*).
Fig. 3. Expression of CXCR4 and CXCL12 mRNA in human
PCa. Secondary data analysis of CXCR4/CXCL12 mRNA was
performed using data published by Dhanasekaran et al. [2001].
Primary data analysis was performed with a Genepix software
package on Cy3-to-Cy5 ratios determined for the individual
genes along with various other quality-control parameters (e.g.,
intensity over local background) [Dhanasekaran et al., 2001].
Data were clustered into normal associated tissues (NAP), BPH,
and localize cancer (PCa) or metastastic cancer (Met PCa).
A graphical format using error bars with 95% CI is presented
where significance from NAT for CXCL12 and CXCR4 was
determined using one-way analysis of variance (ANOVA) with
the level of significance set at P<0.05 (*).
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cells. CXCR4 mRNA levels were highest in the
LNCaP cells, with no significant difference in
expression between the LNCaP C4-2B and PC3
cell lines (Fig. 4A). When the cells were stimu-
lated for 1 h with increasing concentrations
of recombinant CXCL12, mRNA for CXCL12
and CXCR4 rapidly declined in each cell type
demonstrating the functionality of CXCR4
receptors, and that CXCL12 mRNA levels are
also influenced by the presence extracellular
CXCL12 (Fig. 4B).
Given that all of metastastic cell lines ex-
pressed CXCL12 mRNA (Fig. 3) and responded
to CXCL12 by altering their expression of
CXCR4 and CXCL12 RNA (Fig. 4), PCa cells
were next examined to determine if they express
CXCL12 protein. For these investigations, pro-
tein levels of CXCL12 was determined using an
commercial ELISA (R&D Systems). As demon-
strated in Figure 5, each of the cells secreted
CXCL12 into their media. While the levels of
CXCL12 secreted by PCa were significantly less
than those secreted by cultured primary HOB
(Fig. 5), the levels of CXCL12 achieved by the
PCa cells are never-the-less biologically rele-
vant for they are able to synergize with G-CSF
to stimulate the proliferation of murine myelo-
monocytic cells (data not presented).
To determine whether the CXCL12 produced
by PCa cells might serve as a growth factor to
stimulate proliferation of the PCa cells in an
autocrine-like fashion, increasing concentra-
tions of recombinant CXCL12 were add PCa
cell cultures under normal growth conditions.
After 3 days cell proliferation was evaluated
colorimetrically using MTT (Sigma, St. Louis,
MO). CXCL12, itself did not alter the growth
rate of any of the cell lines examined (data not
presented). Similar investigations were then
performed under serum free conditions and
these too failed to demonstrate a proliferative
response of any of the PCa cells tested to
exogenous CXCL12. We next evaluated if con-
ditioned medium derived from BMSCs could
synergize with recombinant CXCL12 to stimu-
lated PCa growth. Our rationale here was that
since PCa cells metastasize to sites of high
CXCL12 production including the marrow, per-
haps there were factors missing in our cultures
that when combined with CXCL12 would
stimulate PCa cell growth. These studies were
undertaken baseduponthe reports thatCXCL12
alone does not stimulate early hematopoietic
progenitor cell growth but is known to synergize
with other growth factors [Grafte-Faure et al.,
2000; Hodohara et al., 2000]. The combination of
Fig. 4. Real time RT-PCR determination of CXCR4 and CXCL12
expression level. RNA recovered from LNCaP, LNCaP C4-2B,
and PC3 cells was reverse transcribed and the levels of CXCR4
and CXCL12 mRNA determined by real-time PCR. Absolute copy
numbers were obtained from standard curves constructed from
serial dilutions of purified CXCL12 and CXCR4 DNA and
normalized against 18S mRNA.
Fig. 5. PCa cell lines secrete CXCL12. Conditioned media from
primary human osteoblasts (HOB) and PCa cell lines were
collected at 72 h and stored at 808C until assayed by antibody
sandwich ELISA assembled with components purchased from
R&D Systems. The data are presented as mean and standard
deviation (SD) for triplicate determinations, and demonstrate
secretion of CXCL12 by PCa cells in culture.
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0, 10, and 25% human stromal cell conditioned
medium to recombinant CXCL12 also failed to
stimulate PCa proliferation, although the con-
ditioned medium itself stimulated proliferation
(data not presented). Similar observations were
made for PCa cell lines grown in the presence of
human osteoblast conditioned medium (data
not shown).
Finally, we directly addressed if CXCL12
derived from the PCa cells themselves acts in
an autocrine fashion to stimulate growth by
neutralizing the CXCL12 produced by the PCa
cells themselves. For these studies neutralizing
antibody to CXCL12 was administered daily
under normal serum or serum free conditions.
At 72 h, the cells were recovered and counted.
Antibody to CXCL12 significantly decreased
the number of LNCaP C4-2B, PC3 recovered
from the cultures relative to isotype match-
ed or vehicle controls in either normal (10%) or
serum-free cultures (Fig. 6). Similar treatments
of LNCaP, had little or no effect on proliferation.
To verify these findings, these investigations
were also performed on a novel PCa cell line
derived from a vertebral metastatic lesion
(VCaP) which was harvested at autopsy fro
a metastatic lesion to a lumbar vertebral body
of a patient with hormone refractory PCa
[Korenchuk et al., 2001]. Like the other PCa
cells, these cells also expressed CXCR4 and
CXCL12 (data not presented). Once again anti-
body to CXCL12 significantly decreased the
number of VCaP recovered from the cultures re-
lative to isotype matched or vehicle controls
in either normal (10%) or serum-free cultures
(Fig. 6). Together these data suggest that in
addition to utilizing CXCR4/CXCL12 as a meta-
stastic mechanism, as a growth factor for PCa
cells, CXCL12 may be used by to establish meta-
stases in CXCL12 rich organs once they have
metastasized.
DISCUSSION
In the present report, we examined human
PCa for their expression of CXCR4 and CXCL12,
as they play a major role in hematopoietic stem
cell homing to the marrow. Using high-density
tissue microarrays constructed from clinical
samples from a large cohort of patients, we ob-
served that the expression of CXCR4 correlated
with increasing malignancy. The data demon-
strate moderate-to-strong CXCR4 protein ex-
pression in clinically localized PCa samples
with cytoplasmic and nuclear localization ob-
served where the levels of CXCR4 protein
expression in malignant epithelia were highest.
Normal epithelium demonstrated predomina-
tely weak cytoplasmic staining. Both prostatic
intraepithelial neoplasia and some atrophic
lesions, also demonstrated cytoplasmic staining
of CXCR4, however, due to the small sample
sizes, were not included in our data. High-grade
(Gleason score, 4þ 4¼ 8) and low-grade PCa
(not shown) also demonstrated strong cytoplas-
mic staining. Similar results were observed in
boney metastases.
Secondary data analysis using a large cohort
study of gene-expression profiles from RNA
obtained from more than 50 normal and neo-
plastic prostate specimen also suggested a rela-
tionship between CXCR4 mRNA levels and
clinical parameters [Dhanasekaran et al., 2001].
CXCR4 expression was elevated in BPH, loca-
lized PCa and metastatic cancers although no
significant differences were seen between the
BPH and increasing tumor grade. This may
suggest that CXCR4 expression in PCa may be
regulated at the protein level in vivo where
rapid turn over of the receptor from intracel-
lular pools has been reported [Cheng et al.,
2000]. At present little is known with regard to
Fig. 6. Neutralizing Antibody to CXCL12 inhibits LNCaP C4-2B
cell proliferation. LNCaP C4-2B cells were seeded overnight at
2,000 cells/well in 96-well plates in medium containing 10%
FCS. Thereafter, the medium was removed and fresh growth
medium was replaced with serum reduced medium. Neutraliz-
ing murine anti-human neutralizing CXCL12 cytokine antibody
(or control) were added daily to a final concentration of 120 mg/
ml. Absolute cell numbers were determined by manual hemo-
cytometer counting and reported as mean SD (n¼4) at 4 days.
*Significant difference from antibody or vehicle control,
P<0.05.
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the CXCR4 regulation in tumors, and whether
expression levels correlates with clinical out-
comes. Far more is known with regards to the
role of CXCR4 in other diseased states where
CXCR4 serves as a co-receptor for some HIV-2
isolates [Caruz et al., 1998; Gupta and Pillar-
isetti, 1999]. During development, CXCR4 is
expressed in a broad range of tissues, including
brain, lymph node, and small intestine [Wegner
et al., 1998; McGrath et al., 1999] functioning in
a number of normal processes including visua-
lization by regulating endothelial branching
and remodeling and CNS development [Feil and
Augustin, 1998; Lazarini et al., 2000]. CXCR4
is highly expressed on monocytes, B cells, and
naive T cells in peripheral blood as well as early
hematopoietic progenitor cells [Aiuti et al.,
1999b]. In fact, CXCR4 expression is elevated
in CD34þ progenitors in bone marrow relative
to CD34þ progenitors in the peripheral blood
[Aiuti et al., 1997]. Suggesting that differential
expression of CXCR4 may be involved in main-
taining hematopoietic progenitor cells in the
marrow and regulating stem cell trafficking
[Aiuti et al., 1997].
Most germane to the present report are data
that demonstrate that tumor progression may
be associated with alterations in CXCR4 mRNA
levels. Muller et al. [2001] reported that CXCR4
and CXCL12 are central players in regulat-
ing Met by demonstrating that normal breast
tissues express little CXCR4, whereas breast
neoplasms express high levels of CXCR4. In this
report, antibody to CXCR4 blocked the meta-
static spread of the tumors to the lung and
lymph nodes [Muller et al., 2001]. Similarly,
CXCR4 mRNA levels are elevated in glioblas-
toma multiforme in regions of angiogenesis
and degeneration, but deceased in areas of
rapid cell proliferation and may be a general
characteristic of neuroblastoma cells that sup-
ports their preferential Met into the bone
marrow [Geminder et al., 2001]. Results con-
sistent with these have also been reported for
human melanoma cell lines and melanoma cells
that had macroscopically infiltrated draining
lymph nodes [Robledo et al., 2001], and for
pancreatic and renal carcinomas [Koshiba et al.,
2000; Gerritsen et al., 2002]. These results are
also consistent with those of Zeelenberg et al.
who transfected CXCL12 fused to a KDEL
sequence into mouse T cell hybridoma TAM2D2.
The SDF–KDEL fusion protein was retained
in the endoplasmic reticulum by the KDEL-
receptor, and bound to CXCR4, which was,
therefore, also retained. This prevented the
Met of the cell line to many different tissues
[Zeelenberg et al., 2001]. Yet CXCR4 is not a
generalized feature of all carcinomas. Several
digestive tract cancers including colon, esopha-
geal, gastric, and premalignant liver disease
(hepatitis C viral infected livers) fail to alter
their expression of the receptor. Moreover,
CXCR4 expression is even reduced in hepato-
cellular carcinomas [Mitra et al., 1999]. These
investigations suggest that CXCR4 may play an
important role in neoplastic events including
the Met of a wide variety of solid tumors in-
cluding prostatecarcinomas [Mulleretal., 2001].
An other intriguing aspect of this investi-
gation is the observation that both members
of the CXCR4/CXCL12 chemokine axis are
expressed by PCa cells in vitro, and in in situ
tumors express CXCL12 mRNA as well as
CXCR4. From these observations found that
PCa cell proliferation was influenced
by CXCL12. This observation is quite surprising
given the possibility that PCa may utilize the
CXCR4 to localize into end organs that supply
high levels of ligand (e.g., bone, lung, liver,
lymphnode [Muller et al., 2001]). Moreover
these observations are consistent with our
previous demonstration that binding of
CXCL12 to CXCR4 in PCa cells activate ERK
signaling that frequently stimulates prolifera-
tion [Taichman et al., 2002]. Recently Zhou et al.
[2002] demonstrated that over expression of
CXCR4 in glioblastoma cell lines enhanced their
growth in soft agar. As with our findings the
treatment of the glioblastoma cell lines with
antibody to CXCR4, or CXCL12, inhibited
proliferation suggesting that CXCR4 gene is
required possibly by preventing apoptosis upon
serum withdrawn [Zhou et al., 2002]. Of note,
not all tumors expressing CXCR4 proliferate in
response to CXCL12 including rhabdomyosar-
coma cells [Libura, 2002]. Thus CXCL12-
induced proliferation, may represent an addi-
tional mechanism for survival utilized by
malignant cells in those PCa cells that metas-
tasize to bone. Moreover, perhaps the ability to
respond in an autocrine or paracrine fashion to
CXCL12 provides a clue as to why some tumors
grow well in CXCL12 rich environments (e.g.,
bone) while others do not [Guise, 2002].
In summary, PCa present great variability
in their ability to metastasize to bone. The
identification of molecules associated with the
CXCR4 and CXCL12 in Prostate Cancer 471
aggressive phenotypes will define PCa subsets
that will ultimately lead to better treatment
strategies. The CXCL12/CXCR4 axis is now
known to modulate the migration and survival
of an increasing array of normal and malig-
nant cell types (including breast [Moore, 2001;
Muller et al., 2001], pancreatic cancers [Koshiba
et al., 2000] glioblastomas [Sehgal et al., 1998;
Rempel et al., 2000], and others [Shibuta et al.,
1997; Begum et al., 1999; Mitra et al., 1999;
Koshiba et al., 2000; Geminder et al., 2001;
Robledo et al., 2001]). Our data is consistent
with the emerging concept that CXCL12 and
CXCR4 expression are associated with increas-
ing malignant potential. The mechanisms of
exactly how CXCL12/CXCR4 participate and
direct the invasive patterns of PCa cells re-
mains to be determined. Future studies will be
required to characterize the mechanisms
whereby CXCL12 alters the adhesion to bone
marrow endothelial cells and invasion into the
extracellular matrix and to directly demon-
strate that blockade of this axis inhibits skeletal
metastases.
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